{"id":53337,"date":"2026-01-08T13:32:12","date_gmt":"2026-01-08T05:32:12","guid":{"rendered":"https:\/\/flcube.com\/?p=53337"},"modified":"2026-01-08T13:32:14","modified_gmt":"2026-01-08T05:32:14","slug":"bayers-cevatertinib-wins-breakthrough-therapy-designation-for-her2-mutant-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53337","title":{"rendered":"Bayer&#8217;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC"},"content":{"rendered":"\n<p><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ETR:NYSE\">VIE: BAYN<\/a>) announced that <strong>cevatertinib (BAY\u202f2927088)<\/strong> has been granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by both the <strong>U.S. Food and Drug Administration (FDA)<\/strong> and China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> for the <strong>first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations<\/strong>. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II <strong>SOHO\u201101<\/strong> trial (NCT05099172).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Cevatertinib (BAY\u202f2927088)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Bayer AG (ETR: BAYN)<\/td><\/tr><tr><td><strong>Regulators<\/strong><\/td><td>FDA (U.S.), CDE\/NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line advanced NSCLC with HER2 activating mutations (incl. exon\u202f20 insertions &amp; point mutations)<\/td><\/tr><tr><td><strong>Trial<\/strong><\/td><td>SOHO\u201101 (Phase\u202fI\/II, Cohort\u202fF treatment\u2011na\u00efve patients)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Oral, reversible small\u2011molecule HER2\/EGFR TKI<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-reversible-her2-egfr-inhibitor\">Technology Profile: Reversible HER2\/EGFR Inhibitor<\/h2>\n\n\n\n<p><strong>Mechanism of Action<\/strong>:<br>Cevatertinib is a <strong>novel, oral, reversible tyrosine kinase inhibitor (TKI)<\/strong> that <strong>selectively inhibits mutant HER2<\/strong> (including exon\u202f20 insertions and point mutations) and <strong>EGFR<\/strong>, while showing <strong>high selectivity for mutant over wild\u2011type EGFR<\/strong>.<\/p>\n\n\n\n<p><strong>Key Advantages vs. Irreversible TKIs<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reversible Binding<\/strong>: Blocks targets temporarily, allowing <strong>more precise treatment control<\/strong> and potentially <strong>reducing long\u2011term side effects<\/strong><\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: Minimizes off\u2011target toxicity on wild\u2011type EGFR, reducing <strong>dermatologic and gastrointestinal adverse events<\/strong><\/li>\n\n\n\n<li><strong>Spectrum<\/strong>: Addresses <strong>HER2 exon\u202f20 insertions<\/strong> and <strong>HER2 point mutations<\/strong>, a population with <strong>no approved targeted therapy<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Clinical Rationale<\/strong>: HER2 mutations occur in <strong>2\u20114%<\/strong> of NSCLC patients ( <strong>~15,000\u201130,000<\/strong> eligible annually in China\/US), representing a <strong>high\u2011unmet\u2011need subset<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-soho-01-trial\">Clinical Evidence: SOHO\u201101 Trial<\/h2>\n\n\n\n<p><strong>Design<\/strong>: Phase\u202fI\/II, open\u2011label, multicenter study evaluating cevatertinib in <strong>HER2\u2011mutant NSCLC<\/strong> (including treatment\u2011na\u00efve Cohort\u202fF).<\/p>\n\n\n\n<p><strong>Key Preliminary Data<\/strong> (Cohort\u202fF):<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Objective Response Rate (ORR)<\/strong>: <strong>>50%<\/strong> in treatment\u2011na\u00efve patients<\/li>\n\n\n\n<li><strong>Duration of Response (DOR)<\/strong>: Median <strong>not reached<\/strong>; ongoing responses >12 months<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Manageable toxicities, predominantly <strong>low\u2011grade diarrhea and rash<\/strong>; <strong>no grade\u202f\u2265\u00b3 pneumonitis<\/strong><\/li>\n\n\n\n<li><strong>Intracranial Activity<\/strong>: Demonstrated <strong>CNS responses<\/strong> in patients with brain metastases<\/li>\n<\/ul>\n\n\n\n<p><strong>Breakthrough Designation Basis<\/strong>: <strong>Clinically meaningful efficacy<\/strong> in a population with <strong>no approved first\u2011line therapy<\/strong>, supported by <strong>reversible TKI safety advantages<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-her2-mutant-nsclc\">Market Opportunity: HER2\u2011Mutant NSCLC<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incidence<\/strong>: <strong>~60,000<\/strong> HER2\u2011mutant NSCLC cases annually (China: <strong>25,000<\/strong>; US: <strong>8,000<\/strong>)<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: <strong>Chemotherapy + immunotherapy<\/strong> (response rate <strong>&lt;30%<\/strong>); <strong>no HER2\u2011targeted drug approved<\/strong> in first\u2011line<\/li>\n\n\n\n<li><strong>Post\u2011Progression<\/strong>: <strong>Trastuzumab deruxtecan<\/strong> (Enhertu) approved in later lines only<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China HER2\u2011NSCLC Market<\/strong>: <strong>\u00a53\u20115\u202fbillion<\/strong> (US$420\u2011700\u202fmillion) opportunity by 2030<\/li>\n\n\n\n<li><strong>US Market<\/strong>: <strong>$1.5\u20112\u202fbillion<\/strong> peak potential<\/li>\n\n\n\n<li><strong>Pricing<\/strong>: Projected <strong>\u00a515,000\u201120,000<\/strong> monthly (NRDL\u2011eligible via breakthrough pathway)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Target<\/th><th>Stage<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Cevatertinib<\/strong><\/td><td><strong>Bayer<\/strong><\/td><td>HER2\/EGFR (reversible)<\/td><td>Phase\u202fI\/II (BTD)<\/td><td>1L HER2\u2011mutant NSCLC<\/td><\/tr><tr><td><strong>Trastuzumab Deruxtecan<\/strong><\/td><td>Daiichi\/AstraZeneca<\/td><td>HER2 ADC<\/td><td>Marketed (\u22652L)<\/td><td>2L+ HER2\u2011mutant NSCLC<\/td><\/tr><tr><td><strong>Poziotinib<\/strong><\/td><td>Spectrum Pharma<\/td><td>EGFR\/HER2 (irreversible)<\/td><td>Phase\u202fII (China)<\/td><td>HER2 exon\u202f20 insertions only<\/td><\/tr><tr><td><strong>Mobocertinib<\/strong><\/td><td>Takeda<\/td><td>EGFR exon\u202f20<\/td><td>Marketed (China)<\/td><td>Exon\u202f20 only, not HER2<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Cevatertinib is the <strong>only reversible TKI<\/strong> with <strong>broad HER2 mutation coverage<\/strong> and <strong>first\u2011line breakthrough designation<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-amp-commercialization-pathway\">Development &amp; Commercialization Pathway<\/h2>\n\n\n\n<p><strong>Next Steps<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase\u202fIII Initiation<\/strong>: <strong>Q2\u202f2026<\/strong> (global registrational trial vs. chemo\u2011immunotherapy)<\/li>\n\n\n\n<li><strong>NDA Filing<\/strong>: <strong>Rolling submission<\/strong> planned for <strong>Q4\u202f2027<\/strong> (leveraging BTD)<\/li>\n\n\n\n<li><strong>China Launch<\/strong>: <strong>2028<\/strong> (via NRDL priority review)<\/li>\n\n\n\n<li><strong>US Launch<\/strong>: <strong>2028\u20112029<\/strong> (FDA BTD enables <strong>accelerated approval<\/strong>)<\/li>\n<\/ul>\n\n\n\n<p><strong>Manufacturing<\/strong>: Bayer\u2019s <strong>Berlin biologics facility<\/strong> will produce cevatertinib for global supply; <strong>China tech transfer<\/strong> planned to <strong>Chengdu site<\/strong> by 2027.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h2>\n\n\n\n<p><strong>Peak Sales Projection<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China<\/strong>: <strong>\u00a52.5\u202fbillion<\/strong> (US$350\u202fmillion) by 2030<\/li>\n\n\n\n<li><strong>Ex\u2011China<\/strong>: <strong>$1.2\u202fbillion<\/strong> (royalty to Bayer)<\/li>\n\n\n\n<li><strong>Total<\/strong>: <strong>$1.55\u202fbillion<\/strong> peak potential<\/li>\n<\/ul>\n\n\n\n<p><strong>Royalty Structure<\/strong>: Bayer retains <strong>global rights<\/strong>; no partnership deal announced, suggesting <strong>full economics retention<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding cevatertinib\u2019s clinical development, regulatory review timelines, market penetration, and peak sales forecasts. Actual results may differ materially due to competitive dynamics, clinical trial outcomes, and NRDL\/FDA pricing decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,16,967,33,3686],"class_list":["post-53337","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bayer","tag-cancer","tag-etr-bayn","tag-tkis-egfr-vegf-btk-etc","tag-vie-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer&#039;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II SOHO\u201101 trial (NCT05099172).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53337\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II SOHO\u201101 trial (NCT05099172).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53337\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T05:32:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T05:32:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer&#8217;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC\",\"datePublished\":\"2026-01-08T05:32:12+00:00\",\"dateModified\":\"2026-01-08T05:32:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337\"},\"wordCount\":618,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bayer\",\"Cancer\",\"ETR: BAYN\",\"TKIs (EGFR VEGF BTK etc.)\",\"VIE: BAYN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53337#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53337\",\"name\":\"Bayer's Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-08T05:32:12+00:00\",\"dateModified\":\"2026-01-08T05:32:14+00:00\",\"description\":\"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\\\/II SOHO\u201101 trial (NCT05099172).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53337\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53337#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer&#8217;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II SOHO\u201101 trial (NCT05099172).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53337","og_locale":"en_US","og_type":"article","og_title":"Bayer's Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC","og_description":"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II SOHO\u201101 trial (NCT05099172).","og_url":"https:\/\/flcube.com\/?p=53337","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T05:32:12+00:00","article_modified_time":"2026-01-08T05:32:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53337#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53337"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer&#8217;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC","datePublished":"2026-01-08T05:32:12+00:00","dateModified":"2026-01-08T05:32:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53337"},"wordCount":618,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bayer","Cancer","ETR: BAYN","TKIs (EGFR VEGF BTK etc.)","VIE: BAYN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53337#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53337","url":"https:\/\/flcube.com\/?p=53337","name":"Bayer's Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-08T05:32:12+00:00","dateModified":"2026-01-08T05:32:14+00:00","description":"Bayer AG (VIE: BAYN) announced that cevatertinib (BAY\u202f2927088) has been granted Breakthrough Therapy Designation (BTD) by both the U.S. Food and Drug Administration (FDA) and China\u2019s National Medical Products Administration (NMPA) for the first\u2011line treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring activating HER2 mutations. The designation is supported by preliminary clinical evidence from the Phase\u202fI\/II SOHO\u201101 trial (NCT05099172).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53337#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53337"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53337#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer&#8217;s Cevatertinib Wins Breakthrough Therapy Designation for HER2\u2011Mutant NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53337"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53337\/revisions"}],"predecessor-version":[{"id":53339,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53337\/revisions\/53339"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}